{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T02:10:28Z","timestamp":1790302228684,"version":"4.1.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T00:00:00Z","timestamp":1764979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":37,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"DOI":"10.1186\/s13075-025-03711-8","type":"journal-article","created":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T04:35:52Z","timestamp":1764995752000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Chimeric antigen receptor (CAR) therapies for precise eradication of pathogenic cells in autoimmunity"],"prefix":"10.1186","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4427-8245","authenticated-orcid":false,"given":"George D.","family":"Kalliolias","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0913-9354","authenticated-orcid":false,"given":"Efthimia K.","family":"Basdra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5803-4527","authenticated-orcid":false,"given":"Athanasios G.","family":"Papavassiliou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,6]]},"reference":[{"issue":"771","key":"3711_CR1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.ado2084","volume":"16","author":"EP English","year":"2024","unstructured":"English EP, Swingler RN, Patwa S, et al. Engineering CAR-T therapies for autoimmune disease and beyond. Sci Transl Med. 2024;16(771):eado2084.","journal-title":"Sci Transl Med"},{"issue":"9","key":"3711_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2025.103859","volume":"24","author":"R Wen","year":"2025","unstructured":"Wen R, Li B, Wu F, et al. Chimeric antigen receptor cell therapy: a revolutionary approach transforming cancer treatment to autoimmune disease therapy. Autoimmun Rev. 2025;24(9):103859.","journal-title":"Autoimmun Rev"},{"key":"3711_CR3","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41586-022-04585-5","volume":"604","author":"RC Larson","year":"2022","unstructured":"Larson RC, Kann MC, Bailey SR, et al. CAR T cell killing requires the IFN\u03b3R pathway in solid but not liquid tumours. Nature. 2022;604:563\u201370.","journal-title":"Nature"},{"issue":"6","key":"3711_CR4","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1056\/NEJMc2107725","volume":"385","author":"D Mougiakakos","year":"2021","unstructured":"Mougiakakos D, Kr\u00f6nke G, V\u00f6lkl S, et al. CD19-targeted CAR T cells in refractory systemic lupus erythematosus. N Engl J Med. 2021;385(6):567\u20139.","journal-title":"N Engl J Med"},{"issue":"8","key":"3711_CR5","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa2308917","volume":"390","author":"F M\u00fcller","year":"2024","unstructured":"M\u00fcller F, Taubmann J, Bucci L, et al. CD19 CAR T-cell therapy in autoimmune disease - a case series with follow-up. N Engl J Med. 2024;390(8):687\u2013700.","journal-title":"N Engl J Med"},{"issue":"10","key":"3711_CR6","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1016\/j.ard.2025.06.2128","volume":"84","author":"Z Hu","year":"2025","unstructured":"Hu Z, Cai S, Yu Y, et al. BCMA-targeted CAR T cell therapy can effectively induce disease remission in refractory lupus nephritis. Ann Rheum Dis. 2025;84(10):1675\u201383.","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"3711_CR7","doi-asserted-by":"publisher","first-page":"3725","DOI":"10.1038\/s41591-025-03937-8","volume":"31","author":"J Feng","year":"2025","unstructured":"Feng J, Huo D, Hong R, et al. Co-infusion of CD19-targeting and BCMA-targeting CAR-T cells for treatment-refractory systemic lupus erythematosus: a phase 1 trial. Nat Med. 2025;31(11):3725\u201336.","journal-title":"Nat Med"},{"issue":"2","key":"3711_CR8","doi-asserted-by":"publisher","first-page":"e83","DOI":"10.1016\/S2665-9913(24)00282-0","volume":"7","author":"J Auth","year":"2025","unstructured":"Auth J, M\u00fcller F, V\u00f6lkl S, et al. CD19-targeting CAR T-cell therapy in patients with diffuse systemic sclerosis: a case series. Lancet Rheumatol. 2025;7(2):e83\u201393.","journal-title":"Lancet Rheumatol"},{"issue":"6","key":"3711_CR9","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1038\/s41591-025-03718-3","volume":"31","author":"F M\u00fcller","year":"2025","unstructured":"M\u00fcller F, Wirsching A, Hagen M, et al. BCMA CAR T cells in a patient with relapsing idiopathic inflammatory myositis after initial and repeat therapy with CD19 CAR T cells. Nat Med. 2025;31(6):1793\u20137.","journal-title":"Nat Med"},{"issue":"6","key":"3711_CR10","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.medj.2024.03.002","volume":"5","author":"F Fischbach","year":"2024","unstructured":"Fischbach F, Richter J, Pfeffer LK, et al. CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosis. Med. 2024;5(6):550\u2013e82.","journal-title":"Med"},{"issue":"23","key":"3711_CR11","doi-asserted-by":"publisher","first-page":"6414","DOI":"10.1016\/j.cell.2025.09.020","volume":"188","author":"C Qin","year":"2025","unstructured":"Qin C, Dong MH, Zhou LQ, et al. Anti-BCMA CAR-T therapy in patients with progressive multiple sclerosis. Cell. 2025;188(23):6414\u2013e2311.","journal-title":"Cell"},{"issue":"12","key":"3711_CR12","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/S1474-4422(23)00375-7","volume":"22","author":"A Haghikia","year":"2023","unstructured":"Haghikia A, Hegelmaier T, Wolleschak D, et al. Anti-CD19 CAR T cells for refractory myasthenia gravis. Lancet Neurol. 2023;22(12):1104\u20135.","journal-title":"Lancet Neurol"},{"issue":"7","key":"3711_CR13","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/S1474-4422(23)00194-1","volume":"22","author":"V Granit","year":"2023","unstructured":"Granit V, Benatar M, Kurtoglu M, et al. Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b\/2a study. Lancet Neurol. 2023;22(7):578\u201390.","journal-title":"Lancet Neurol"},{"key":"3711_CR14","doi-asserted-by":"publisher","first-page":"103621","DOI":"10.1016\/j.eclinm.2025.103621","volume":"90","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Liu D, Zhang Z, et al. Anti-BCMA\/CD19 CAR T cell therapy in patients with refractory generalized myasthenia gravis: a single-arm, phase 1 trial. EClinicalMedicine. 2025;90:103621.","journal-title":"EClinicalMedicine"},{"issue":"9","key":"3711_CR15","doi-asserted-by":"publisher","first-page":"100704","DOI":"10.1016\/j.medj.2025.100704","volume":"6","author":"MH Dong","year":"2025","unstructured":"Dong MH, Mei ZC, Zhou LQ, et al. Anti-BCMA CAR-T cell therapy in relapsed\/refractory chronic inflammatory demyelinating polyneuropathy. Med. 2025;6(9):100704.","journal-title":"Med"},{"issue":"22","key":"3711_CR16","doi-asserted-by":"publisher","first-page":"2282","DOI":"10.1056\/NEJMc2502297","volume":"392","author":"L Zhang","year":"2025","unstructured":"Zhang L, Gao Z, Pan H, et al. BCMA-targeted T-cell engager for autoimmune hemolytic anemia after CD19 CAR T-cell therapy. N Engl J Med. 2025;392(22):2282\u20134.","journal-title":"N Engl J Med"},{"issue":"10","key":"3711_CR17","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1136\/ard-2024-225785","volume":"83","author":"W Wang","year":"2024","unstructured":"Wang W, He S, Zhang W, et al. BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial. Ann Rheum Dis. 2024;83(10):1304\u201314.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"3711_CR18","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1146\/annurev-immunol-083122-044829","volume":"42","author":"I Abeles","year":"2024","unstructured":"Abeles I, Palma C, Meednu N, Payne AS, Looney RJ, Anolik JH. B cell-directed therapy in autoimmunity. Annu Rev Immunol. 2024;42(1):103\u201326.","journal-title":"Annu Rev Immunol"},{"issue":"6","key":"3711_CR19","doi-asserted-by":"publisher","first-page":"e434","DOI":"10.1016\/S2665-9913(24)00377-1","volume":"7","author":"M Scherlinger","year":"2025","unstructured":"Scherlinger M, Nocturne G, Radic M, et al. CAR T-cell therapy in autoimmune diseases: where are we and where are we going? Lancet Rheumatol. 2025;7(6):e434\u201347.","journal-title":"Lancet Rheumatol"},{"issue":"11","key":"3711_CR20","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1038\/s41577-024-01035-3","volume":"24","author":"JB Chung","year":"2024","unstructured":"Chung JB, Brudno JN, Borie D, Kochenderfer JN. Chimeric antigen receptor T cell therapy for autoimmune disease. Nat Rev Immunol. 2024;24(11):830\u201345.","journal-title":"Nat Rev Immunol"},{"issue":"9","key":"3711_CR21","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adt0795","volume":"11","author":"S Oh","year":"2025","unstructured":"Oh S, Khani-Habibabadi F, O\u2019Connor KC, Payne AS. Composition and function of AChR chimeric autoantibody receptor T cells for antigen-specific B cell depletion in myasthenia gravis. Sci Adv. 2025;11(9):eadt0795.","journal-title":"Sci Adv"},{"key":"3711_CR22","doi-asserted-by":"publisher","unstructured":"Tur C, Eckstein M, Bucci L et al. Effects of different B-cell-depleting strategies on the lymphatic tissue. Ann Rheum Dis. 2025;S0003-4967(25):04174-3. https:\/\/doi.org\/10.1016\/j.ard.2025.06.2120. Epub ahead of print.","DOI":"10.1016\/j.ard.2025.06.2120"},{"key":"3711_CR23","doi-asserted-by":"publisher","unstructured":"Garantziotis P, Beretta L, Lindblom J, et al. Differential molecular signatures in response to CD19-CAR T cell therapy compared with conventional pharmacotherapy in systemic lupus erythematosus. Ann Rheum Dis. 2025;S0003\u201349672504187\u20131. https:\/\/doi.org\/10.1016\/j.ard.2025.06.2132. Epub ahead of print.","DOI":"10.1016\/j.ard.2025.06.2132"},{"issue":"11","key":"3711_CR24","doi-asserted-by":"publisher","first-page":"3713","DOI":"10.1038\/s41591-025-03899-x","volume":"31","author":"X Wang","year":"2025","unstructured":"Wang X, Zhang Y, Wang H, et al. Allogeneic CD19-targeting T cells for treatment-refractory systemic lupus erythematosus: a phase 1 trial. Nat Med. 2025;31(11):3713\u201324.","journal-title":"Nat Med"},{"issue":"18","key":"3711_CR25","doi-asserted-by":"publisher","first-page":"4890","DOI":"10.1016\/j.cell.2024.06.027","volume":"187","author":"X Wang","year":"2024","unstructured":"Wang X, Wu X, Tan B, et al. Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis. Cell. 2024;187(18):4890-4904.e9.","journal-title":"Cell"},{"key":"3711_CR26","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/s41422-025-01128-1","volume":"35","author":"C Yang","year":"2025","unstructured":"Yang C, Sun C, Tan B, et al. Allogeneic anti-CD19 CAR-T cells induce remission in refractory systemic lupus erythematosus. Cell Res. 2025;35:607\u20139.","journal-title":"Cell Res"},{"issue":"10","key":"3711_CR27","first-page":"100749","volume":"6","author":"D Wang","year":"2025","unstructured":"Wang D, Wang X, Tan B, et al. Allogeneic CD19-targeted CAR-T therapy in refractory systemic lupus erythematosus achieved durable remission. Medicine (Baltimore). 2025;6(10):100749.","journal-title":"Medicine (Baltimore)"},{"key":"3711_CR28","doi-asserted-by":"publisher","unstructured":"Gao J, Li M, Sun M et al. Efficacy and safety of allogeneic CD19 CAR NK-cell therapy in systemic lupus erythematosus: a case series in China. Lancet. 2025:S0140-6736(25):01671-X. https:\/\/doi.org\/10.1016\/S0140-6736(25)01671-X. Epub ahead of print.","DOI":"10.1016\/S0140-6736(25)01671-X"},{"issue":"16","key":"3711_CR29","doi-asserted-by":"publisher","first-page":"4225","DOI":"10.1016\/j.cell.2025.05.038","volume":"188","author":"X Wang","year":"2025","unstructured":"Wang X, Zhang Y, Jin Y, et al. An iPSC-derived CD19\/BCMA CAR-NK therapy in a patient with systemic sclerosis. Cell. 2025;188(16):4225\u2013e3812.","journal-title":"Cell"},{"issue":"6753","key":"3711_CR30","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1126\/science.ads8473","volume":"388","author":"TL Hunter","year":"2025","unstructured":"Hunter TL, Bao Y, Zhang Y, et al. In vivo CAR T cell generation to treat cancer and autoimmune disease. Science. 2025;388(6753):1311\u20137.","journal-title":"Science"},{"issue":"1","key":"3711_CR31","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1038\/s41467-024-46448-9","volume":"15","author":"M Doglio","year":"2024","unstructured":"Doglio M, Ugolini A, Bercher-Brayer C, et al. Regulatory T cells expressing CD19-targeted chimeric antigen receptor restore homeostasis in systemic lupus erythematosus. Nat Commun. 2024;15(1):2542.","journal-title":"Nat Commun"},{"key":"3711_CR32","doi-asserted-by":"publisher","first-page":"1613878","DOI":"10.3389\/fimmu.2025.1613878","volume":"16","author":"D Wu","year":"2025","unstructured":"Wu D, Xu-Monette ZY, Zhou J, et al. CAR T-cell therapy in autoimmune diseases: a promising frontier on the horizon. Front Immunol. 2025;16:1613878.","journal-title":"Front Immunol"},{"issue":"1","key":"3711_CR33","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s00296-024-05772-5","volume":"45","author":"L Kattamuri","year":"2025","unstructured":"Kattamuri L, Mohan Lal B, Vojjala N, et al. Safety and efficacy of CAR-T cell therapy in patients with autoimmune diseases: a systematic review. Rheumatol Int. 2025;45(1):18.","journal-title":"Rheumatol Int"},{"issue":"6","key":"3711_CR34","doi-asserted-by":"publisher","first-page":"e424","DOI":"10.1016\/S2665-9913(25)00091-8","volume":"7","author":"M Hagen","year":"2025","unstructured":"Hagen M, M\u00fcller F, Wirsching A, et al. Local immune effector cell-associated toxicity syndrome in CAR T-cell treated patients with autoimmune disease: an observational study. Lancet Rheumatol. 2025;7(6):e424\u201333.","journal-title":"Lancet Rheumatol"},{"issue":"2","key":"3711_CR35","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/s41591-023-02767-w","volume":"30","author":"BL Levine","year":"2024","unstructured":"Levine BL, Pasquini MC, Connolly JE, et al. Unanswered questions following reports of secondary malignancies after CAR-T cell therapy. Nat Med. 2024;30(2):338\u201341.","journal-title":"Nat Med"},{"issue":"8","key":"3711_CR36","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1056\/NEJMc2504588","volume":"393","author":"A Aleman","year":"2025","unstructured":"Aleman A, Van Oekelen O, Melnekoff DT, et al. Targeted therapy of CAR\u2009+\u2009T-cell lymphoma after anti-BCMA CAR T-cell therapy. N Engl J Med. 2025;393(8):823\u20135.","journal-title":"N Engl J Med"},{"issue":"6","key":"3711_CR37","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1056\/NEJMoa2411507","volume":"392","author":"K Perica","year":"2025","unstructured":"Perica K, Jain N, Scordo M, et al. CD4\u2009+\u2009T-cell lymphoma harboring a chimeric antigen receptor integration in TP53. N Engl J Med. 2025;392(6):577\u201383.","journal-title":"N Engl J Med"},{"issue":"22","key":"3711_CR38","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1056\/NEJMoa2401361","volume":"390","author":"MP Hamilton","year":"2024","unstructured":"Hamilton MP, Sugio T, Noordenbos T, et al. Risk of second tumors and T-cell lymphoma after CAR T-cell therapy. N Engl J Med. 2024;390(22):2047\u201360.","journal-title":"N Engl J Med"},{"issue":"22","key":"3711_CR39","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1056\/NEJMoa2401530","volume":"390","author":"M Ozdemirli","year":"2024","unstructured":"Ozdemirli M, Loughney TM, Deniz E, et al. Indolent CD4\u2009+\u2009CAR T-cell lymphoma after Cilta-cel CAR T-cell therapy. N Engl J Med. 2024;390(22):2074\u201382.","journal-title":"N Engl J Med"},{"issue":"7","key":"3711_CR40","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1056\/NEJMp2400209","volume":"390","author":"N Verdun","year":"2024","unstructured":"Verdun N, Marks P. Secondary cancers after chimeric antigen receptor T-cell therapy. N Engl J Med. 2024;390(7):584\u20136.","journal-title":"N Engl J Med"},{"issue":"4","key":"3711_CR41","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1038\/s41591-024-02826-w","volume":"30","author":"G Ghilardi","year":"2024","unstructured":"Ghilardi G, Fraietta JA, Gerson JN, et al. T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy. Nat Med. 2024;30(4):984\u20139.","journal-title":"Nat Med"},{"issue":"3","key":"3711_CR42","doi-asserted-by":"publisher","first-page":"e212","DOI":"10.1016\/S2665-9913(24)00240-6","volume":"7","author":"K Lungova","year":"2025","unstructured":"Lungova K, Putman M. Barriers to CAR T-cell therapy in rheumatology. Lancet Rheumatol. 2025;7(3):e212\u20136.","journal-title":"Lancet Rheumatol"}],"container-title":["Arthritis Research & Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-025-03711-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-025-03711-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-025-03711-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T22:07:16Z","timestamp":1768342036000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13075-025-03711-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,6]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3711"],"URL":"https:\/\/doi.org\/10.1186\/s13075-025-03711-8","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,6]]},"assertion":[{"value":"3 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors agreed to the publication of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8"}}